Michal Grzmil

Villigen, AG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

The "Two-Step Boost" for [177Lu]Lu-PP-F11N Therapy: Optimization of Tumor Uptake by Premedication.

The "Two-Step Boost" for [177Lu]Lu-PP-F11N Therapy: Optimization of Tumor Uptake by Premedication.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 11, 2025

Comparative evaluation of radiolabeled bombesin analogs [177Lu]Lu-AMBA and [177Lu]Lu-RM2 for targeting GRPR in glioblastoma model.

Comparative evaluation of radiolabeled bombesin analogs [177Lu]Lu-AMBA and [177Lu]Lu-RM2 for targeting GRPR in glioblastoma model.

Journal: Nuclear medicine and biology

Published: March 28, 2025

Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis.

Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis.

Journal: International journal of molecular sciences

Published: March 21, 2025

161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas.

161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 24, 2024

Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers.

Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers.

Journal: Scientific reports

Published: July 31, 2023

Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer.

Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer.

Journal: Cancers

Published: November 16, 2022

Signaling Network Response to α-Particle-Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors.

Signaling Network Response to α-Particle-Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 05, 2022

Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT).

Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT).

Journal: Journal of hematology & oncology

Published: May 23, 2022

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [177Lu]Lu-PP-F11N.

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [177Lu]Lu-PP-F11N.

Journal: Pharmaceutics

Published: November 19, 2021

Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy.

Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy.

Journal: Pharmaceutics

Published: September 22, 2020

Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N.

Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N.

Journal: Theranostics

Published: February 28, 2020

SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

Journal: Neuro-oncology

Published: February 06, 2018

Showing 1-12 of 21

Last Updated: 09/26/2026